Logo image of PCVX

VAXCYTE INC (PCVX) Stock Fundamental Analysis

NASDAQ:PCVX - Nasdaq - US92243G1085 - Common Stock - Currency: USD

30.65  +1.53 (+5.25%)

After market: 30.65 0 (0%)

Fundamental Rating

3

PCVX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. While PCVX has a great health rating, there are worries on its profitability. PCVX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

PCVX had negative earnings in the past year.
PCVX had a negative operating cash flow in the past year.
In the past 5 years PCVX always reported negative net income.
PCVX had a negative operating cash flow in each of the past 5 years.
PCVX Yearly Net Income VS EBIT VS OCF VS FCFPCVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

PCVX has a better Return On Assets (-13.21%) than 84.33% of its industry peers.
The Return On Equity of PCVX (-14.03%) is better than 89.08% of its industry peers.
Industry RankSector Rank
ROA -13.21%
ROE -14.03%
ROIC N/A
ROA(3y)-21.33%
ROA(5y)-23.51%
ROE(3y)-23.3%
ROE(5y)-26.19%
ROIC(3y)N/A
ROIC(5y)N/A
PCVX Yearly ROA, ROE, ROICPCVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PCVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCVX Yearly Profit, Operating, Gross MarginsPCVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

PCVX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PCVX has been increased compared to 5 years ago.
There is no outstanding debt for PCVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PCVX Yearly Shares OutstandingPCVX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
PCVX Yearly Total Debt VS Total AssetsPCVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

PCVX has an Altman-Z score of 11.00. This indicates that PCVX is financially healthy and has little risk of bankruptcy at the moment.
PCVX's Altman-Z score of 11.00 is amongst the best of the industry. PCVX outperforms 90.14% of its industry peers.
PCVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11
ROIC/WACCN/A
WACCN/A
PCVX Yearly LT Debt VS Equity VS FCFPCVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

2.3 Liquidity

A Current Ratio of 12.75 indicates that PCVX has no problem at all paying its short term obligations.
The Current ratio of PCVX (12.75) is better than 86.27% of its industry peers.
A Quick Ratio of 12.75 indicates that PCVX has no problem at all paying its short term obligations.
PCVX's Quick ratio of 12.75 is amongst the best of the industry. PCVX outperforms 86.27% of its industry peers.
Industry RankSector Rank
Current Ratio 12.75
Quick Ratio 12.75
PCVX Yearly Current Assets VS Current LiabilitesPCVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.14% over the past year.
EPS 1Y (TTM)8.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PCVX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.36% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.62%
EPS Next 2Y-10.48%
EPS Next 3Y-6.33%
EPS Next 5Y30.36%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCVX Yearly Revenue VS EstimatesPCVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B
PCVX Yearly EPS VS EstimatesPCVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PCVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PCVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCVX Price Earnings VS Forward Price EarningsPCVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCVX Per share dataPCVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

A cheap valuation may be justified as PCVX's earnings are expected to decrease with -6.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.48%
EPS Next 3Y-6.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PCVX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VAXCYTE INC

NASDAQ:PCVX (4/17/2025, 8:00:00 PM)

After market: 30.65 0 (0%)

30.65

+1.53 (+5.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2025-02-25/amc
Earnings (Next)05-12 2025-05-12
Inst Owners112.55%
Inst Owner Change0%
Ins Owners0.49%
Ins Owner Change12.58%
Market Cap3.95B
Analysts87.06
Price Target140.99 (360%)
Short Float %9.82%
Short Ratio10.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.61%
Min EPS beat(2)12.92%
Max EPS beat(2)28.3%
EPS beat(4)3
Avg EPS beat(4)15.11%
Min EPS beat(4)-9.49%
Max EPS beat(4)28.7%
EPS beat(8)5
Avg EPS beat(8)1.53%
EPS beat(12)5
Avg EPS beat(12)-2.03%
EPS beat(16)9
Avg EPS beat(16)1.18%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.99%
PT rev (3m)-7.78%
EPS NQ rev (1m)-0.11%
EPS NQ rev (3m)3.86%
EPS NY rev (1m)3.99%
EPS NY rev (3m)3.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.19
P/tB 1.19
EV/EBITDA N/A
EPS(TTM)-3.79
EYN/A
EPS(NY)-4.61
Fwd EYN/A
FCF(TTM)-4.44
FCFYN/A
OCF(TTM)-3.52
OCFYN/A
SpS0
BVpS25.67
TBVpS25.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.21%
ROE -14.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.33%
ROA(5y)-23.51%
ROE(3y)-23.3%
ROE(5y)-26.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1701.54%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.75
Quick Ratio 12.75
Altman-Z 11
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1359.67%
Cap/Depr(5y)905.15%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.29%
EPS Next Y-21.62%
EPS Next 2Y-10.48%
EPS Next 3Y-6.33%
EPS Next 5Y30.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-44.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-12.18%
EBIT Next 3Y-9.59%
EBIT Next 5YN/A
FCF growth 1Y-56.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.51%
OCF growth 3YN/A
OCF growth 5YN/A